



June 2, 2021

Hon. Justin Trudeau Office of the Prime Minister 80 Wellington Street Ottawa, ON K1A 0A2

Dear Prime Minister,

RE: Patient Groups concerns over actions of PMPRB

We are writing to you today to register our strong concern regarding plans made by the PMPRB to discredit patient groups who disagree with proposed changes the regulator has brought forward and to ask you to delay the implementation of those changes while a full investigation of the activities of the PMPRB can take place.

In an internal PMPRB document, obtained through an ATIP request, PMPRB staff allege that "opponents" of the PMPRB Guidelines reforms, including patient groups representing people living with rare diseases and the cystic fibrosis patient community, in particular, are spreading "disinformation" about the potential negative implications of these changes. This memo lays out a communications plan to discredit the stakeholder and patient community who oppose the reforms.

We want to be clear that the use of the word "disinformation" is both highly inflammatory and dangerous. "Disinformation" is defined as an intentional effort to mislead people. This was a deliberate vocabulary choice by PMPRB officials that should not be overlooked. Unfortunately, PMPRB took the inappropriate step of characterizing a policy disagreement as an intentional effort to mislead people and maligned the motives of patient groups working on behalf of all Canadians. These actions go far beyond disregarding the input of patient





organizations, which has been our concern with the PMPRB consultations for some time and instead seek to work against the patient community actively.

We cannot condemn this characterization and these actions strongly enough.

However, it is not simply inappropriate for a regulator to act in this manner; it is dangerous. Policy debate and disagreement is the hallmark of a healthy democracy. To malign and mischaracterize the actions of those that disagree with the PMPRB undermines our democratic values and calls into question the regulator's objectivity and fitness to fulfill its mandate.

Our view is that the PMPRB has operated with a lack of good faith throughout the consultation period and in the lead up to the coming into force of the revised guidelines. Rather than leading an open and transparent consultation process, where patient input was, at minimum, respected, the PMPRB ignored patient input, sidelined patient groups, and is now working to discredit them in the face of their continued concerns.

The actions of PMPRB demonstrate a flagrant abuse of power. Therefore, we are calling on the federal government to delay the implementation of the PMPRB changes while a full investigation of the activities of the PMPRB can occur.

Sincerely,

Doug Earle

President & CEO, Fighting Blindness Canada | Vaincre la cécité Canada On behalf of:

ALS Society of Canada

Canadian Cancer Survivor Network

Canadian Hospice Palliative Care Association





Canadian Association of PNH Patients

Coalition Priorité Cancer au Québec

Colorectal Cancer Canada

Cure SMA Canada

Cystic Fibrosis Canada

Fighting Blindness Canada

Lung Health Foundation

MitoCanada

Ovarian Cancer Canada

PROCURE – The Force Against Prostate Cancer

Québec Breast Cancer Foundation

The Leukemia & Lymphoma Society of Canada

Cc: Hon. Patty Hajdu, Minister of Health

Hon. Chrystia Freeland, Deputy Prime Minister and Minister of Finance

Hon. François-Philippe Champagne, Minister of Innovation, Science and

Industry

Hon. Dominic LeBlanc, Minister of Intergovernmental Affairs

Members of the House of Commons Standing Committee on Health:

Mr. Ron McKinnon

Ms. Michelle Rempel Garner

Mr. Luc Theriault

Mr. John Barlow

Mr. Don Davies

Mr. Chris d'Entremont

Mr. Mike Kelloway

Mr. Larry Maguire

Ms. Jennifer O'Connell

Mr. Marcus Powlowski

Ms. Sonia Sidhu

Mr. Tony Van Bynen

Clerk of the Privy Council